Moderna’s stock doubles on promising cancer-vaccine results

Moderna announced results from a clinical trial of a cancer vaccine candidate that combines an mRNA therapy with the drug Keytruda. The company's stock price doubled following the announcement. Moderna did not release the specific efficacy data in the provided text.

Next story